Ultrasound tumour treatment developer HistoSonics has been backed by Michigan’s Mints initiative and student-run Wolverine Venture Fund.

HistoSonics, a US-based ultrasound tumour treatment developer based on University of Michigan research, today raised an initial $8.3m in series B funding from investors including the university’s Michigan Investment in New Technology Startups (Mints) program.
The round was led by VC firm Venture Investors and backed by University of Michigan’s student-run Wolverine Venture Fund, as well as Fletcher Spaght Ventures, the investment arm of strategic consultancy Fletcher Spaght.
VC firm Hatteras Venture Partners also took part in the…